Company: VERA
Filing Date: 2025-12-10
Form Type: 424B5
Source: 0001193125-25-314244
Chunk: 5

Company: Vera Therapeutics, Inc.
Filing Date: 2025-12-10
Form: 424B5
Chunk 5
---
 will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks and trade names. We do not intend our use or display of
other entities’ trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other entity.

S-2

The offering

| Class A common stock offered by us | 6,138,108 of our Class A common stock. |

| Option to purchase additional shares | We have granted the underwriters an option to purchase up to an additional 920,716 shares of our Class A common stock from us. This option is exercisable, in whole or in part, for a period of 30 days following the date of this prospectus 
 supplement.                                                                                                                                                                                                                                   |

| Class A common stock to be outstanding immediately after this offering | 70,032,953 shares of our Class A common stock (or 70,953,669 shares if the underwriters exercise their option to purchase additional shares in full). |

| Use of proceeds | We estimate that our net proceeds from this offering will be approximately $244.5 million, or approximately $281.3 million if the underwriters’ option to purchase additional shares of our Class A common stock from us is exercised in 
 full, in each case, after deducting underwriting discounts and commissions and estimated offering expenses payable by us.                                                                                                                |

| We currently intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, to fund the potential commercial launch of atacicept in IgAN, which we anticipate would occur in                
 2026, if approved, and the development of new clinical indications for atacicept, and the remainder for general corporate purposes, including working capital, operating expenses and capital expenditures. See “Use of proceeds” for 
 additional information.                                                                                                                                                                                                               |

| Risk factors | See “Risk factors” beginning on page S-5 of this prospectus supplement and other information included and incorporated by reference in this prospectus supplement and the accompanying prospectus 
 for a discussion of factors that you should carefully consider before deciding to invest in our Class A common stock.                                                                             |

| Nasdaq Global Market symbol | “VERA.” |

The number of shares of our Class A common stock to be outstanding immediately after this offering set forth above is based on 63,894,845 shares of our Class A common stock outstanding as of September 30, 2025, but excludes: